Tigecycline - Trillium Therapeutics
Latest Information Update: 24 Oct 2021
At a glance
- Originator University Health Network
- Developer Memorial Sloan-Kettering Cancer Center; Princess Margaret Hospital (University of Toronto); University Health Network; University of California at Los Angeles; University of Kansas
- Class Antibacterials; Glycylcyclines; Small molecules
- Mechanism of Action Mitochondrial protein inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia